Stockscreener 앱 받기
121.80
1.40%
-1.73
시간 외 거래:
122.81
1.01
+0.83%
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen (BIIB): JP Morgan Lowers Price Target But Maintains Neutral Rating | BIIB Stock News - GuruFocus
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
JPMorgan Adjusts Price Target for Biogen (BIIB) Following Q1 Report | BIIB Stock News - GuruFocus
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Red Biotechnology Market to Witness Remarkable Growth with - openPR.com
Biogen Inc. (NASDAQ:BIIB) Receives Average Rating of "Hold" from Analysts - MarketBeat
Voya Investment Management LLC Decreases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Lowered to $187.00 at HC Wainwright - MarketBeat
Robert W. Baird Cuts Biogen (NASDAQ:BIIB) Price Target to $255.00 - MarketBeat
Biogen (NASDAQ:BIIB) Posts Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Northern Trust Corp Has $237.05 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Integrated Wealth Concepts LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Trimmed by MML Investors Services LLC - MarketBeat
Schonfeld Strategic Advisors LLC Has $12.16 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Call Transcript - Insider Monkey
AQR Capital Management LLC Has $81.91 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Maintains Outperform Rating Despite Lowered Price Target | BIIB Stock News - GuruFocus
Biogen's Lean Pivot Attracts Renewed Investor Interest - Finimize
Biogen (BIIB): Canaccord Genuity Lowers Price Target to $220 | BIIB Stock News - GuruFocus
TD Cowen Adjusts Price Target on Biogen to $175 From $200 - marketscreener.com
Morgan Stanley Adjusts Price Target on Biogen to $146 From $152 - marketscreener.com
Biogen price target lowered to $146 from $152 at Morgan Stanley - TipRanks
Biogen price target lowered to $205 from $217 at RBC Capital - TipRanks
Oppenheimer Adjusts Biogen (BIIB) Price Target to Reflect Outloo - GuruFocus
BIIB: HC Wainwright & Co. Lowers Price Target for Biogen | BIIB Stock News - GuruFocus
Biogen (BIIB) Price Target Cut by RBC Capital Amid Positive Outl - GuruFocus
Biogen (BIIB) Maintains Rating, Price Target Lowered by Baird | - GuruFocus
Biogen (BIIB) Maintains Rating, Price Target Lowered by Baird | BIIB Stock News - GuruFocus
Morgan Stanley Adjusts Price Target for Biogen (BIIB) After Q1 R - GuruFocus
Biogen (BIIB) Target Price Cut Amid Market Adjustments | BIIB St - GuruFocus
Biogen (BIIB) Maintains Hold Rating by Needham Analyst | BIIB St - GuruFocus
Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025 - MSN
Biogen (BIIB) Price Target Reduced by Baird Analyst | BIIB Stock News - GuruFocus
Biogen (BIIB) Price Target Reduced by Canaccord Despite Strong Q - GuruFocus
Biogen (BIIB) Price Target Reduced by Canaccord Despite Strong Q1 Performance | BIIB Stock News - GuruFocus
Lido Advisors LLC Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar - MSN
The Zacks Analyst Blog Highlights: Encana, Enbridge, BankAtlantic Bancorp, BB&T and Biogen IdecPress Releases - ADVFN
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight - GuruFocus
Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ... - Yahoo Finance
Quarry LP Buys New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Aquatic Capital Management LLC Buys 10,845 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Biogen reports Q1 EPS $3.02, consensus $2.96 - TipRanks
Biogen Inc. Reports Strong Q1 2025 Results - TipRanks
Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact - insights.citeline.com
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics - MSN
Biogen Inc. Earnings Call Highlights Growth and Challenges - TipRanks
SEC Form S-3ASR filed by Biogen Inc. - Quantisnow
Biogen (BIIB) Boosted by New Products as Revenue Climbs - GuruFocus
BIOGEN INC. SEC 10-Q Report - TradingView
Price T Rowe Associates Inc. MD Increases Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
William Blair Forecasts Biogen's Q2 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact - Benzinga
Shareholders Claim Biogen Skipped $50M Drug Payment - Law360
Stifel maintains Biogen stock Hold rating, $144 target post-earnings By Investing.com - Investing.com India
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
Stifel maintains Biogen stock Hold rating, $144 target post-earnings - Investing.com
Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income - simplywall.st
Biogen (BIIB) Reports Q1 Earnings and Revenue Growth - GuruFocus
Truist Financial Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut - TradingView
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
1.53%
자본화:
|
볼륨(24시간):